Get the Stockscreener App
2.64
4.68%
-0.14
Inmed Pharmaceuticals Inc stock is traded at $2.64, with a volume of 16,632.
It is down -4.68% in the last 24 hours and down -11.96% over the past month.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
See More
Previous Close:
$2.78
Open:
$2.66
24h Volume:
16,632
Relative Volume:
0.19
Market Cap:
$3.19M
Revenue:
$4.96M
Net Income/Loss:
$-6.82M
P/E Ratio:
-0.0404
EPS:
-65.4
Net Cash Flow:
$-6.64M
1W Performance:
-1.85%
1M Performance:
-11.96%
6M Performance:
-38.37%
1Y Performance:
-53.91%
1-Day Range:
$2.6101
$2.7047
1-Week Range:
$2.6101
$2.9339
52-Week Range:
$1.72
$15.70
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Name
Inmed Pharmaceuticals Inc
Sector
Phone
(604) 669-7207
Address
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
2.64 | 3.68M | 4.96M | -6.82M | -6.64M | -65.40 |
|
HLN
Haleon Plc Adr
|
11.26 | 49.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
164.90 | 72.86B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.7702 | 4.35M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.58 | 44.57B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.90 | 19.24B | 16.54B | -1.64B | 749.00M | -1.45 |
Inmed Pharmaceuticals Inc Stock (INM) Latest News
InMed Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Registration Now Open For Tribe Public’s Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMed’s Management Team On November 17, 2022 - Seeking Alpha
InMed Pharmaceuticals (NASDAQ:INM) Trading Down 11.5% – Here’s What Happened - Defense World
Biotech Alert: Searches spiking for these stocks today - TipRanks
InMed Pharmaceuticals Advances Drug Pipeline Amid Financial Challenges - TipRanks
InMed Reports Third Quarter Fiscal 2025 Financial Results and Pr - GuruFocus
InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update - Newsfile
InMed Pharmaceuticals Inc. SEC 10-Q Report - TradingView
SEC Form PRE 14A filed by InMed Pharmaceuticals Inc. - Quantisnow
Press Release Distribution & PR Platform - ACCESS Newswire
InMed Pharmaceuticals cancels special shareholder meeting By Investing.com - Investing.com Canada
InMed Pharmaceuticals cancels special shareholder meeting - Investing.com
InMed Pharmaceuticals sets date for special shareholder meeting By Investing.com - Investing.com South Africa
InMed Pharmaceuticals sets date for special shareholder meeting - Investing.com
InMed Pharmaceuticals stock hits 52-week low at $1.72 - Investing.com Australia
InMed Pharmaceuticals stock hits 52-week low at $1.72 By Investing.com - Investing.com South Africa
InMed Pharmaceuticals : Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview - MarketScreener
InMed Pharmaceuticals Stock Hits 52-Week Low at $2.34 By Investing.com - Investing.com India
InMed Pharmaceuticals Stock Hits 52-Week Low at $2.34 - Investing.com India
InMed Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
InMed Pharmaceuticals Struggles with Losses Amid Revenue Decline - MSN
InMed Pharmaceuticals Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Defense World
InMed Pharmaceuticals Board Reshuffle After Director Resignation - TipRanks
InMed Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Yahoo Finance
InMed Pharmaceuticals Inc. (INM) reports earnings - Quartz
InMed Advances INM-089 for Dry AMD Treatment with New Intravitreal Formulation - TipRanks
Inmed selects IVT formulation of INM-089 for dry AMD - BioWorld Online
InMed advances AMD treatment with promising IVT drug formulation - MSN
Revolutionary Eye Drug INM-089 Achieves 10X Therapeutic Levels in Macular Degeneration Treatment - StockTitan
Inmed Pharmaceuticals Inc (INM-Q) QuotePress Release - The Globe and Mail
InMed Pharmaceuticals (NASDAQ: INM) Secures International Patent for Novel Compounds - Defense World
InMed Pharmaceuticals Secures Key Patent for Cannabinoid Analogs - TipRanks
InMed Pharmaceuticals secures international patent - Investing.com India
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds - Newsfile
InMed Secures Breakthrough 20-Year Patent in Mexico for Novel Cannabinoid Compounds - StockTitan
Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise - Asianet Newsable
InMed Pharmaceuticals (NASDAQ: INM) Announces Positive Results from INM-901 Alzheimer’s Disease Study - Defense World
InMed Hails Alzheimer's Study, Stocks Shoot Higher - Baystreet.ca
InMed announces ‘positive’ results from in vivo preclinical Alzheimer’s study - TipRanks
InMed’s INM-901 Shows Promising Results in Preclinical Alzheimer’s Study - TipRanks
Inmed Pharmaceuticals Inc Stock (INM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):